Montanova Capital LLC Has $6.87 Million Stock Position in DexCom, Inc. $DXCM

Key Points

• Montanova Capital increased its DexCom stake by 221.9% in the second quarter, purchasing 70,300 additional shares for a total holding of 101,980 shares valued at approximately $6.87 million. Institutional investors collectively own 97.75% of the company.
• Analysts remain broadly bullish, with a “Moderate Buy” consensus and an average price target of $88.71; individual targets range from $90 to $105.
• DexCom reported quarterly earnings of $0.70 per share, exceeding estimates by $0.09, while revenue reached $1.31 billion and grew 13.1% year over year. The stock opened at $91.06, near its 52-week high of $92.59.

Montanova Capital LLC increased its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 221.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 101,980 shares of the medical device company's stock after purchasing an additional 70,300 shares during the period. Montanova Capital LLC's holdings in DexCom were worth $6,868,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. MassMutual Private Wealth & Trust FSB grew its stake in DexCom by 15.4% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company's stock worth $77,000 after buying an additional 153 shares in the last quarter. V Square Quantitative Management LLC increased its holdings in DexCom by 1.8% in the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company's stock valued at $604,000 after buying an additional 172 shares during the period. Essex Financial Services Inc. raised its position in shares of DexCom by 5.7% in the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company's stock valued at $204,000 after buying an additional 175 shares in the last quarter. Keel Point LLC lifted its holdings in shares of DexCom by 3.1% during the 4th quarter. Keel Point LLC now owns 6,473 shares of the medical device company's stock worth $430,000 after acquiring an additional 193 shares during the period. Finally, Integrated Wealth Concepts LLC lifted its holdings in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company's stock worth $227,000 after acquiring an additional 196 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Raymond James Financial reissued a "strong-buy" rating and issued a $94.00 price objective on shares of DexCom in a research note on Friday, July 31st. Truist Financial set a $93.00 target price on DexCom and gave the company a "buy" rating in a report on Friday, July 31st. UBS Group set a $96.00 price objective on DexCom and gave the company a "buy" rating in a research note on Tuesday, July 28th. Royal Bank Of Canada boosted their target price on shares of DexCom from $85.00 to $90.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. Finally, Robert W. Baird set a $105.00 price target on DexCom in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $88.71.

DexCom Trading Up 0.3%

NASDAQ DXCM opened at $91.06 on Tuesday. The business has a 50 day simple moving average of $79.64 and a 200 day simple moving average of $71.77. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The stock has a market capitalization of $34.36 billion, a P/E ratio of 35.99, a P/E/G ratio of 1.53 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company's revenue was up 13.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.48 earnings per share. Research analysts expect that DexCom, Inc. will post 2.64 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Kevin R. Sayer sold 26,756 shares of the business's stock in a transaction on Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider owned 328,970 shares in the company, valued at $25,106,990.40. The trade was a 7.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $85.32, for a total transaction of $170,640.00. Following the transaction, the director directly owned 48,852 shares in the company, valued at approximately $4,168,052.64. This represents a 3.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 75,600 shares of company stock worth $5,673,342 over the last ninety days. 0.28% of the stock is owned by company insiders.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source